Vermont Health Access
Pharmacy Benefit Management Program
DUR Workgroup Meeting Minutes: 4/19/05

Board Members:

James Gray, M.D., Chair	Cheryl Gibson, M.D.	Jeff Firlik, R.Ph.
Frank Landry, M.D.	Rich Harvie, R.Ph.	Michael Scovner, M.D.
Virginia Hood, M.D.	Stuart Graves, M.D.	John Low, R.Ph.

Staff:

Joshua Slen, OVHA Director	Ann Rugg, OVHA	Felicia Montineri, R.Ph. FHSC
Scott Strenio, M.D. OVHA	Kathy Hasbrouck, OVHA	

Guests:

Christine Barnett, Astra Zeneca	Natalie Prairie, Forest	Geoffrey Gallo, Astra Zeneca
David Anderson, Astra Zeneca	Andrine Swenson, Lilly	Don Foy, Lilly
John Ewashko, Lilly	Carl Pepe, GSK	Kristen Ryan, Astellas
Raub Bertel, BIPI	Julee Frow, BIPI	Doug Brooks, BIPI
Maryellen Darragh, RN	Paul Harrington, VMS	Paul Rowe, BI
Gordon Maher, Takeda	Jennifer Buttle, Merck	Robert Polan, Johnson & Johnson
Eileen Mevin, GSK	Mike Smith, Sanofi-Aventis	Tracy Lynn, Pfizer

Scott Strenio, M.D. called the meeting to order at the DUR Board Meeting site in Williston.

1. Differentiating P&T from DUR Activities of the Vermont DUR Board.

A discussion ensued about the increased need for both P&T work as well as DUR activities to be completed within a very short timeframe. Board members were asked if they wished to separate P&T activities from DUR Board activities.

Board Decision:

Continue with both P&T and DUR activity recommendations.

2. P&T Process- Review of Workgroup notes.

The board discussed ways to make the P&T advisory and recommendation process more expeditious, how to continue to utilize expert opinion and what legal issues surround utilizing a write only electronic forum. Selection of drugs to be reviewed must be systematic. One board member suggested a consensus document to aid in making recommendations regarding drugs. The operational aspects of discussing drugs via an electronic format will be brought to the legal council within AHS.

Board Decision:

P&T review activities will be done in advance of the DUR Board meeting. Selection of drugs to be discussed will be made via a template or a standardized methodology. At the next DUR Board meeting, the Board will review a template/methodology to be used in the future.

Material for drugs chosen by the selection process would be presented via formal documents for board members' perusal 2 weeks before the DUR Board Meeting.

Board members would discuss the therapeutics of drugs via an electronic format. For those drugs members had questions about, additional information could be presented at the DUR Board meeting. After clarification, the board would vote on status of the drug.

3. Re/Defining the Role of the Vermont DUR.

The Drug Utilization Review Board will continue their Drug Utilization Review and P&T advisory responsibilities to the Office of Vermont Health Access Pharmacy Benefit Management program.